Beam Therapeutics' fundamentals suggest a clinical-stage gene editing platform that remains dependent on episodic collaboration milestones, with revenue falling from $31.7M in 2026Q1 to just $307K in 2026Q3 while operating losses reached $141.3M in the latest quarter.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | -$1.28-11.3% vs -$1.15 | $307,000-96.5% vs $9M |
Q3 2026 Aug 4, 2026 | -$1.18-6.3% vs -$1.11 | $490,000-97.0% vs $16M |
Q2 2026 May 7, 2026 | -$0.91-4.6% vs -$0.87 | $32M+189.1% vs $11M |
Q1 2026 Feb 24, 2026 | -$0.10+91.2% vs -$1.13 | $114M+877.9% vs $12M |
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript
Beam Therapeutics NASDAQ: BEAM reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A (GSD1a), showing dose-dependent improvements in fasting tolerance and reductions in cornstarch supplementation among the first six treated patients.
Benchmark BEAM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Beam Therapeutics Inc. (BEAM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $4.65 | $839.87M | -4.39 | 55.28% | -4613.11% | -188.27% | — | |
| $2.38 | $259.88M | -15.80 | — | — | -5.76% | — |
Beam Therapeutics Inc. (BEAM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Beam Therapeutics Inc. (BEAM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Aug 4, 2026·SEC
Jun 8, 2026·SEC
Get notified when BEAM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Beam Therapeutics Inc. (BEAM) stock FAQ — growth, dividends, profitability & financials explained
Beam Therapeutics Inc. (BEAM) reported $146.6M in revenue over the trailing twelve months. Revenue was $139.7M in fiscal year 2025.
Beam Therapeutics Inc. (BEAM) grew revenue by 163.3% over the trailing twelve months, compared with the twelve months before.
No. Beam Therapeutics Inc. (BEAM) reported a net loss of $107.1M over the trailing twelve months.
Beam Therapeutics Inc. (BEAM) had a return on equity (ROE) of -9.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Beam Therapeutics Inc. (BEAM) had negative free cash flow of $398.2M over the trailing twelve months.
